Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Blueprint Genetics | RCV000788440 | SCV000927555 | pathogenic | not provided | 2018-03-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001384756 | SCV001584401 | pathogenic | Granulomatous disease, chronic, autosomal recessive, cytochrome b-negative | 2024-11-27 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Tyr87*) in the CYBA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CYBA are known to be pathogenic (PMID: 10910929, 20167518, 22876374). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with chronic granulomatous disease (PMID: 20167518). ClinVar contains an entry for this variant (Variation ID: 636575). For these reasons, this variant has been classified as Pathogenic. |
Natera, |
RCV001830682 | SCV002089437 | pathogenic | Chronic granulomatous disease | 2020-09-28 | no assertion criteria provided | clinical testing |